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Background: This study reports on the development of a novel method for achieving ex vivo
reanimation of hearts from a porcine donation after circulatory death (DCD) model without
the use of donor pretreatment.
Methods: Porcine hearts (n ¼ 23) were procured 10e29 min after confirmation of asystole. All
hearts underwent initial flush with AQIX RS-I solution (London, UK). A 2-h preservation
period followed: group 1 hearts (n1en11) were preserved using static cold storage, group 2
hearts (n12en17) were preserved using oxygenated, hypothermic machine perfusion (MP),
and group 3 hearts (n18en23) were subjected to retrograde oxygen persufflation. Reperfu-
sion was performed on a Langendorff modification of a Model 33 Functional Circulation
circuit. In hearts n16en23, a dialysis circuit was incorporated into the circuit to facilitate
removal of metabolites. The experimental protocol was allowed to follow an evolutionary
course, with the aim of achieving greater success with reanimation.
Results: In group 1 (static cold storage), 7 of the 11 hearts (63.6%) achieved reanimation on
the ex vivo circuit. Two of the six hearts (33.3%) in group 2 (MP) were successfully reani-
mated. All the six hearts (100%) in group 3 (persufflation) were successfully reanimated.
The period of sustained reanimation increased when dialysis was incorporated into the
circuit with a maximum of 300 min.
Conclusions: Porcine DCD hearts after 29 min of warm ischemia can be reanimated using the
method described. A mechanism of reoxygenation (oxygenated MP or coronary sinus ox-
ygen persufflation) during preservation appears mandatory for hearts from DCDs. Per-
sufflation was associated with a higher probability of successful reanimation. Dialysis in
the warm phase was useful in removing metabolites that could interfere with reanimation.antation, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, UK. Tel.: þ44 0 191 223
com (O.A. Mownah), david.talbot@nuth.nhs.uk (D. Talbot).
ier Inc. All rights reserved.
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number of heart transplants performed
Kingdom over the last 15 y [3,4].The results demonstrate the potential of DCDs to counter the decline affecting heart
transplantation.
ª 2014 Elsevier Inc. All rights reserved.1. Background therapies such as dysrhythmia prevention during the agonalForpatientswithend-stageheart failure,heart transplantation
remains the optimum treatment [1]. However, the increasing
problem of shortage of suitable hearts from donors after
brainstem death (DBD) has led to a decline in the number of
heart transplants being performed (Fig. 1). In the United
Kingdom,<150proceduresareoccurringperannumcompared
with roughly 300 per annum during the 1980s and 1990s [2e4].
In kidney, liver, and lung transplantation, the decline in the
number of DBDs has led to the expansion of donation after
circulatory death (DCD) programs. Improvements in pro-
curement and storage of DCD kidneys and lungs mean that
outcomes are now comparable with DBD organs [5e7].
Cardiac transplantationhasyet toextend into routineuseof
DCDs. Factors preventing the use of DCD hearts concern the
significantly higher metabolic demand of the heart compared
with other organs because of greater susceptibility to the
deleterious effects of warm ischemia. It should be noted that
thefirst humanheart transplantation in 1967 involved a period
of normothermic ischemia [8]. However, in the 1970s, after the
formal definition of brainstem death, the cardiac transplant
community established DBDs as the sole source of hearts.
A reexamination of the potential of DCD heart trans-
plantation is becoming current because of a number of animal
models which have reported that hearts transplanted into
pigs and dogs can work sufficiently to provide circulatory
support in the early stages after implantation [9,10], with
Gundry et al. [11] demonstrating success with a primate
model. As well as the initial experiences with heart trans-
plantation described by Barnard et al. [8], there has been recent
experience of human heart transplantation using hearts from
DCDs in a pediatric setting.
A notable element of the protocols involved in DCD heart
transplantation studies thus far, in both the animal models
and the clinical environment, is the use of donor pretreat-
ment. All cases found in the literature included donor anti-
coagulation before the determination of circulatory arrest.
Additional pretreatments have included cardioprotectivehe decline in the
in the Unitedperiod [10]. In several nations including the United Kingdom,
such donor pretreatments for DCDs are currently prohibited
[12]. An experimental model of DCD heart reanimation in a
model with no pretreatment has yet to be described.
In this study, we report on our investigations into DCD
heart reanimation using a porcine DCD model. We have
devised a protocol devoid of any donor pretreatments, in
accordance with current United Kingdom law, and using an
ex vivo circuit to perform organ perfusion and reanimation
under normothermic conditions. These experiments were
designed to follow an evolutionary course with adjustments
made to the experimental protocol based on the ongoing
findings. The overall aim was to have a retrieval and preser-
vation method conducive to facilitating reanimation. The
design of the ex vivo circuit was similarly improved with
sequential experiments to permit satisfactory cardiac perfu-
sion aiming for prolonged periods of reanimation.2. Methods
2.1. Porcine DCD model
All animal work was performed under conditions of the Home
Office Project License (PPL 6004164). Twenty-three cross-
Yorkshire Landrace pigs with a mean weight of 29.7  5.9 kg
were used in the study. Before the experiments, the animals
were housed and treated humanely in accordance with the
United Kingdom Home Office Animals (Scientific Procedures)
Act 1986. Animals were brought to the facility 7 d before
euthanasia for acclimatization.
A summary of the experimental protocol can be viewed in
Figure 2. Before simulation of aDCD scenario, each animalwas
premedicated with an intramuscular injection of ketamine
(300 mg), medetomidine (1.2 mg), and diazepam (10 mg). Cir-
culatory death was caused by one of the two methods: excess
administration of phenobarbitone or exsanguination. For
n1en11, n14, n15, n18, n22, andn23, an ear veinwas cannulated,
and an overwhelming dose of intravenous phenobarbitone
(4.5 g) was delivered. Circulatory arrest was confirmed by
auscultation of heart sounds. General anesthesia was admin-
istered to animals n12, n13, n16, n17, and n19en21, with
exsanguination performed after thoracolaparotomy by open-
ing of the inferior vena cava. Confirmation of circulatory arrest
was performed on visual inspection of the heart.
2.2. Surgical procedure and initial flush
Hearts were explanted after 10e29 min after determination of
circulatory arrest. The blood (500 mL) was collected from the
inferior vena cava using a suction device. The suction tubing
and container were pretreated with low-molecular-weight
heparin (25,000 IU) and streptokinase (375,000 IU). The blood
was then passed through a leukocyte filter (LeukoGuard RS;
Fig. 2 e The experimental protocol. Flow chart showing the experimental protocol. WI [ warm ischaemia.
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4Ce8C until perfusion on the ex vivo circuit. After the
10e29 min of warm ischemia, the heart was placed in a bowl
of cold AQIX RS-I solution. RS-I is a novel nonephosphate-
buffered preservation and normothermic perfusion solution
with a formulation based on constituents present in human
interstitial fluid (Table 1).
Immediately after hypothermic immersion in RS-I, an
initial flush was delivered to the heart using a Tibbs arterial
cannula directly into both coronary artery ostia. Group 1
(n1en11) underwent initial flush with 250 mL of RS-I at room
temperature. This initial flush also contained low-molecular-
weight heparin (12,500 U), streptokinase (375,000 U), and
phentolamine (0.25 mg). The initial flush for groups 2 and 3
(n12en23) was preoxygenated by persufflating the RS-I with
oxygen at a flow rate of 2 L/min for 15 min. Furthermore, the
initial flush for groups 2 and 3 was supplemented with the
addition of N-acetylcysteine (100 mg). For n18en23, the
following drugs were added to the initial flush: insulin (60 IU),
dexamethasone (16 mg), and co-amoxiclav (120 mg). Asubsequent flush of 250mLwas delivered in the samemanner
immediately afterward. This second flush was either cold RS-I
(n1en6) or cold University of Wisconsin (UW) solution
(n7en11). Hearts from n12en23 did not receive a second flush.
2.3. Cardiac preservation groups 1e3
After the flush, group 1 hearts were preserved as follows:
n1en8 were preserved for 2 h using static cold storage (SCS) in
RS-I solution with n9en11 undergoing SCS for the same period
in UW solution. Group 2 hearts (n12en17) underwent
oxygenated, hypothermic machine perfusion (MP) with UW
solution for 2 h. This was performed using a LifePort (Organ
Recovery Systems, Zaventem, Belgium) with a pressure into
the aortic root set at 30 mm Hg. Oxygen was persufflated into
the circulating UW solution at a rate of 0.5 L/min. Group 3
hearts (n18en23) underwent retrograde oxygen persufflation
via the coronary sinus, at a pressure of 10e12 mm Hg, for a
period of 2 h. At the onset of persufflation, a 21-gauge needle
was used to make 12 holes in the myocardium to permit the
Table 1 e The components of AQIX RS-I solution.
Components Concentration
NaCl 110 mmol/L
KCl 5 mmol/L
CaCl2 1.25 mmol/L
MgCl2 0.45 mmol/L
NaHCO3 (buffer) 25 mmol/L
BES 5 mmol/L
D-glucose 10 mmol/L
Glycerol 0.11 mmol/L
L-glutamate 0.30 mmol/L
L-glutamine 0.40 mmol/L
L-aspartate 0.02 mmol/L
L-carnitine 0.05 mmol/L
Choline chloride 0.01 mmol/L
TPP (cocarboxylase) 40 nmol/L
Human (recombinant) insulin 28 mIU
pH 7.13  7.41  0.5 at 10Ce37C
Osmolarity 286 mOsmol/L
BES ¼ N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid; TPP ¼
thiamine diphosphoric acid ester tetrahydrate.
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monitor the persufflation pressure, and the heart was
immersed in cold RS-I during this time (Fig. 3).
2.4. Heart preparation for perfusion
A cannula was secured in the aorta with a silk tie, to lie 5 mm
distal to the coronary ostia. The openings of the pulmonary
veins entering the left atriumwere closedwith silk ties, except
for one vein, which was cannulated. The inferior and superior
vena cavae were closed with silk ties, and the proximal pul-
monary artery vented to allow cardiac venous blood to drain
back into the circuit.
2.5. The ex vivo circuit and dialysis
Reperfusion was performed on a Langendorff modification of
a Model 33 Functional Circulation (Functional Circulation,
Northbrook, IL) circuit (Fig. 4). The top reservoir provided a
gravity-driven column of oxygenated blood into the coronaryFig. 3 e The persufflation procedure. The procedure used to del
simple manometer) into the coronary sinus. Small punctures in
version of figure is available online.)arteries. The second reservoir provided inflow into the left
atrium to deliver preload to the heart when in working mode.
Venous blood was driven by a roller pump through a hollow
fiber oxygenator (Chalice Medical, Nottinghamshire, UK)
before being returned to the top reservoir. Temperature con-
trol was provided by a circulating water bath (9100 Series
Temperature Controller; PolyScience, Niles, IL), which pro-
vided heat exchange at the oxygenator and the reactor (the
glass container which housed the heart).
For n16en23, a dialysis filter was added to run in parallel to
the circuit (Fig. 5). The arrangement used an FX8 Capillary
Dialyser (Fresenius Medical Care, Bad Homburg, Germany)
with two roller pumps. Venous blood from the reactor was
diverted to the dialysis filter and returned to the circuit
proximal to the oxygenator. The dialysate was made by mix-
ing deionized water and phosphate to a commercially avail-
able hemodialysate concentrate (A/5; FreseniusMedical Care).2.6. Perfusion
The circuit was primed with the leukocyte-depleted blood
(500 mL) plus 300 mL of RS-I. Clamps were placed on the
outflow tubes draining both reservoirs. The heart was con-
nected to the circuit by attachment of the aortic cannula to the
top reservoir outflow and the left atrial cannula to the second
reservoir outflow. Perfusion was commenced together with
cautious rewarming. For hearts n1 and n2, the top reservoir
was unclamped completely to deliver high initial flows into
the aortic root. For subsequent hearts, a variable clamp was
used to control initial flow with a steady increase of flow over
the first 30min “Venous” and oxygenated bloodwere regularly
sampled and tested in a blood gas analyser (RAPIDLab 1200;
Siemens AG, Munich, Germany). This provided data including
pO2, pH, lactate, and potassium concentrations.
Activity of the heart wasmonitored. Fibrillatory activity, as
well as time and duration of reanimation, was recorded.
Interventionswere carried out, such as electrical defibrillation
and drugs (calcium, magnesium, and adrenaline) were
administered to facilitate reanimation. With the heart iniver oxygen at a pressure of 10e12 mm Hg (measured by a
the myocardium allowed excess oxygen to escape. (Color
Fig. 4 e The ex vivo circuit. The ex vivo reperfusion circuit
(Langendorff modification of a Model 33 Functional
Circulation) together with the dialysis arrangement.
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released allowing preload to enter the left atrium.3. Results
Reanimation of the DCD hearts on the ex vivo circuit was
achieved in 15 of the 23 hearts (65%). The first two hearts failed
(as well as the n4 and n10). Four of the six hearts in group 2
(oxygenated MP) failed to reanimate, whereas all group 3
(persufflation) hearts reanimated. On the instances of failure
to reanimate, the myocardium was noted to have developed
gross edema soon after the start of perfusion. After these
initial experiments, electrical defibrillationwas used routinely
to establish sinus rhythm (from n3 onward) with consistent
success. Drugs were also introduced into the protocol with
good effect. Adrenaline as well as calcium, magnesium, and
antibiotics administered into the circuit were all found toFig. 5 e Schematic of the circuit. This schematic diagram illustr
parallel dialysis circuit. (Color version of figure is available onlicontribute to successful reanimation (refer to Table 2 for a
detailed account of the experiments).
The dialyser was able to efficiently remove lactate from the
system and maintain physiological pH and potassium con-
centration. The experiments, which incorporated dialysis
(n16en23), involved sustained reanimation from 3e5 h on the
circuit. The heat exchange aspect of the circuitmaintained the
perfusate at 33Ce34C. The oxygenator was able to provide
pO2 measurements of 80e100 kPa.4. Discussion
In this study, we have described the steps taken to achieve a
reproducible method for reanimating porcine hearts after
exposure to 10e29 min of warm ischemia. The results of the
experiments underline the potential for using hearts sourced
from DCDs in clinical heart transplantation. This protocol
underwent various amendments, detailed in the methods, to
improve organ preservation and the ex vivo circuit. Several
early hearts failed, but as the experiments progressed, a
reproducible method was established leading to reanimation
of a heart subjected to 29 min of warm ischemia with pro-
longed activity on the circuit lasting 5 h. This study has shown
the potential of AQIX RS-I as a perfusate for DCD hearts. The
benefits of RS-I have been reported in a study of rat hearts
showing superior cardioprotection when using an RS-I based
solution versus St Thomas’ Hospital solution [13].
The amendments made to the experimental protocol dur-
ing the course of the study were based on observations during
the initial hearts with the aim of achieving successful rean-
imation for prolonged periods. The best results came from the
last six hearts. These hearts underwent oxygen persufflation
during the preservation process and dialysis while on the
circuit. Using persufflation as a means of introducing oxygen
into the organ during the cold phase has been shown toates the circuit with the heart in “working” mode with the
ne.)
Table 2 e Results table.
Heart
number
Mode of
death
Warm
ischemic
time (min)
Cold phase Normothermic phase
Flush Preservation Drugs Electrical
defibrillation
Dialysis Activity
Group 1
1 Phenobarbitone 10 250 mL of RS-I SCS in RS-I None None None Fibrillation only and nil
ventricular contractions
2 Phenobarbitone 10 250 mL of RS-I SCS in RS-I None None None Fibrillation only and
nil ventricular contractions
3 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline Yes None Reanimation
4 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline Yes None Fibrillation only and
nil ventricular contractions
5 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline Yes None Reanimation
6 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline Yes None Reanimation
7 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline and calcium Yes None Reanimation
8 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline and calcium Yes None Reanimation
9 Phenobarbitone 10 250 mL of RS-I SCS in RS-I Adrenaline and calcium Yes None Reanimation
10 Phenobarbitone 10 250 mL of RS-I SCS in UW solution Adrenaline and calcium Yes None Fibrillation only and
nil ventricular contractions
11 Phenobarbitone 10 250 mL of RS-I SCS in UW solution Adrenaline and calcium Yes None Reanimation
Group 2
12 Exsanguination 12 250 mL of
oxygenated RS-I
MP in oxygenated
UW solution
Adrenaline and calcium Yes None Fibrillation only and
nil ventricular contractions
13 Exsanguination 12 250 mL of
oxygenated RS-I
MP in oxygenated
UW solution
Adrenaline and calcium Yes None Nil reanimation
14 Phenobarbitone 16 250 mL of
oxygenated RS-I
MP in oxygenated
UW solution
Adrenaline and calcium Yes None Nil reanimation
15 Phenobarbitone 18 250 mL of
oxygenated RS-I
MP in oxygenated
UW solution
Adrenaline, calcium, and
magnesium
Yes None Reanimation
16 Exsanguination 14 250 mL of
oxygenated RS-I
MP in oxygenated
UW solution
Adrenaline, calcium, and
magnesium
Yes Yes Nil reanimation
17 Exsanguination 12 250 mL of
oxygenated RS-I
MP in oxygenated
UW solution
Adrenaline, calcium, and
magnesium
Yes Yes Reanimation
Group 3
18 Phenobarbitone 22 250 mL of
oxygenated RS-I
O2 persufflation
(in RS-I)
Adrenaline, calcium, and
magnesium
Yes Yes Reanimation
19 Exsanguination 18 250 mL of
oxygenated RS-I
O2 persufflation
(in RS-I)
Adrenaline, calcium, and
magnesium
Yes Yes Reanimationdsustained for 2 h
20 Exsanguination 18 250 mL of
oxygenated RS-I
O2 persufflation
(in RS-I)
Adrenaline, calcium, and
magnesium
Yes Yes Reanimationdintermittent for 2 h
21 Exsanguination 22 250 mL of
oxygenated RS-I
O2 persufflation
(in RS-I)
Adrenaline, calcium, magnesium,
and co-amoxiclav
Yes Yes Reanimationdsustained for 5 h
22 Phenobarbitone 20 250 mL of
oxygenated RS-I
O2 persufflation
(in RS-I)
Adrenaline, calcium, magnesium,
and co-amoxiclav
Yes Yes Reanimationdsustained for 3 h
23 Phenobarbitone 29 250 mL of
oxygenated RS-I
O2 persufflation
(in RS-I)
Adrenaline, calcium, magnesium,
and co-amoxiclav
Yes Yes Reanimationdsustained for 5 h
Results of each experiment with groups assigned according to the preservation technique used. Group 1 hearts underwent SCS, group 2 hearts underwent oxygenated MP, and group 3 hearts un-
derwent retrograde coronary sinus persufflation. Dialysis was incorporated into the reperfusion protocol from n16 onward.
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tion [14e16]. Fischer et al. [17] described the positive effects of
persufflation on myocardial preservation, and following our
observations, we would advocate its use in preserving DCD
hearts. Furthermore, the technique as we have described is
straightforward and inexpensive. An additional reasonwhy the
latter hearts may have shown superior reanimation was the
inclusion of several drugs in the initial flush. N-acetylcysteine
was used as a free-radical scavenger to counter the potential
ischemiaereperfusion injury resulting from persufflating oxy-
gen into the ischemic myocardium. Dexamethasone has an
important role in the inhibition of proinflammatory mediators
(e.g., tumor necrosis factor a, interleukin 6, and interleukin 8)
produced during reperfusion [18]. Insulin promotes cellular
potassium uptake, thereby stabilizing cardiomyocytes.
A problem encountered in the experiments was the
increasing lactate concentrations in the circulating blood as
the period on the circuit progressed. Lactate accumulation is
associated with impairment of glycolytic reactions in the
myocardium and reduced anaerobic adenosine triphosphate
production [19]. This problem was addressed by including a
modified dialysis circuit to run within the circuit. Lactate
removal was found to enable prolonged periods of sustained
reanimation on the circuit, with the longest period of sus-
tained reanimation at 5 h. The dialysis feature also allowed pH
buffering and maintenance of physiological potassium levels.
Eight of the 23 hearts failed to reanimate. These occurrences
were broadly spoken at the beginning of the study and much
was learned from these initial failures. These hearts were
macroscopically found to be satisfactory at retrieval and after
preservation. However, soon after warm perfusion had been
commenced, they had rapidly developed gross edema with a
fixed contracture of the myocardium. This phenomenon has
previously been described in the literature as “stone heart”
formation [20]. The basis for this complication lies in the failure
of cardiomyocyte ion-exchange mechanisms. Ischemia causes
rapid depletion in the adenosine triphosphate stores of the
metabolically active cardiomyocytes with an accumulation
intracellular Naþ. This results in overwhelming Ca2þ influx via
the NaþeCa2þ exchange mechanism causing activation of the
myocardial contractile apparatus. The consequent contractile
necrosis bands which form cause irreversible damage, with
functional recovery no longer possible [21]. There is evidence
that the use of NaþeHþ exchange inhibitors (cariporide) in
previous DCD heart transplantation models is associated with
improved functional recovery [9,10]. A further technique
demonstrating protection against stone heart formation is
controlled initial myocardial reperfusion. When this has been
coupled with steady rewarming, there has been an improve-
ment in the functional recovery of DCD hearts [22]. The hearts
in our studywere found to reanimate consistently by using this
technique of cautious initial reperfusion.
Crucially in our study, the donor animal received no pre-
treatment. Several studies have reported on DCD animal
experimentation [9e11] and the initial results of clinical pe-
diatric DCD heart transplantation [23]. However, on all occa-
sions, the donor was anticoagulatedwith intravenous heparin
before circulatory arrest. Thus, our method, if extended to the
clinical environment, would comply with the current laws in
the United Kingdom concerning organ DCD [12].Ex vivo reanimation is proposed as the method central to
DCD heart transplantation. Reanimation of a heart in vivo
would likely be prevented by ethical concerns, that is, the
donor has been declared dead after a period of circulatory
arrest so that the donation can proceed, but now, the dead
donor has a cardiac output. Aswell as circumventing this issue,
the ex vivo technique allows the reanimated heart to (1) be
transported if the recipient is at a distant site and (2) undergo
functional testing. Conductance catheters could be introduced
to assess contractility and echocardiography performed for
assessment of ejection fraction. This form of viability testing
would be essential before deciding on the suitability for
transplantation [24]. Ex vivo lung perfusion has highlighted the
importance of viability testing and has contributed to the high
success rates achieved with DCD lung transplantation [25].
Furthermore, a period of normothermic ex vivo perfusion has
been shown to improve the condition of DCD lungs [26].
The circuit designed in this study could also be extended
for use in the assessment of marginal DBD hearts. There is
currently a high rate of organ decline on the basis of poor
function. Ex vivo perfusion would be the ideal method of
assessing such organs, potentially allowing more transplants
to successfully proceed. In addition, placing a DBD heart on
the circuit would eliminate exposure of the graft to the dele-
terious effects of the “catecholamine storm” associated with
brainstem death, which is known to cause myocardial
dysfunction [27,28].
The cold phase reoxygenation step we used could be per-
formed in practice during transport of a donated heart. The
reoxygenation via MP was not successful with us, but this was
probably because the flow rates were not high enough to close
the aortic valve as we were using a renal MP system. So,
reoxygenation with MP is still a possible alternative to per-
sufflation [29].
The less transportable Langendorf circuit described here
could be used at the base hospital. Our circuit perfused the
coronary arteries under gravity. Thismethod of gravity-driven
flow provided adequate myocardial perfusion, whereas
pressure-driven flow (using pumps) can be associated with
myocardial damage. Gravity-driven reperfusion leads to filling
in accordance with the coronary vascular resistance, avoiding
ischemia with hypoperfusion, or hemorrhage with hyper-
perfusion. Furthermore, the height of the top reservoir
providing the coronary perfusion can be altered to increase
the perfusion pressure. In our system, the top reservoir pro-
vided a column of blood analogous to afterloadwhen the heart
was in working mode. Our modified Langendorff approach
allows preload to be given via the second lower reservoir
inflow into the left atrium during the working mode.
This study was treated as an evolutionary process to
identify the ideal method and conditions to achieve rean-
imation of a porcine DCD heart. The primary end points were
the presence and duration of reanimation. Quantitative data
regarding the quality of the organs have not been studied at
this early stage but will form the basis of future studies. There
were difficulties in maintaining a physiological temperature
of 36C in our circuit, prompting several adjustments to be
considered for our future experiments. The temperature
averaged between 33C and 34C, which is short of the phys-
iological conditions we aimed to simulate with our circuit.
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was not performed as part of this study. Incorporation of
transplantation into our animal model is an essential step
toward assessing the true potential for using DCD-sourced
hearts in the clinical environment. Despite transplantation
not occurring in this study, it remains a key part of this
research and will form the basis of our future experiments.
Several studies have investigated the potential number of
hearts that could be contributed to the donor pool by using
DCDs. Noterdaeme et al. [30] reported a potential increase in
donor hearts of 15%, which would correlate with a potential
40% decrease in the number of patients dying while on the
waiting list. With an ever increasing number of patients
requiring transplantation and based on the findings of this
study, we would propose an increased focus on DCDs as an
untapped resource to expand the donor pool.5. Conclusions
Hearts sourced from DCDs using our porcine model can be
successfully reanimated. Reanimation can be achieved
following cold phase preservation using SCS, oxygenated MP,
or retrograde coronary sinus persufflation. But DCD hearts
were most likely to reanimate after the use of retrograde oxy-
gen persufflation. The addition of dialysis to the ex vivo circuit
was a straightforwardmethod for maintaining the integrity of
the blood in the circuit, thus enabling more success with
reanimation. AQIX RS-I solution has shown promise as a po-
tential preservation solution for hearts in transplantation.
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